Emiliano Rodriguez-Caulo

Dr. Emiliano Rodriguez-Caulo

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
EREmiliano Rodriguez-Caulo
Emiliano Rodriguez-Caulo
AGAna Guijarro-Contreras
Ana Guijarro-Contreras
AGArantza Guzón
Arantza Guzón
JOJuan Otero-Forero
Juan Otero-Forero
MMMaría José Mataró
María José Mataró
MJManuel Jiménez-Navarro
Manuel Jiménez-Navarro

3 January 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
EREmiliano Rodriguez-Caulo
Emiliano Rodriguez-Caulo
DMDiego Macías
Diego Macías
AAAlejandro Adsuar
Alejandro Adsuar
AFAndrea Ferreiro
Andrea Ferreiro
JAJavier Arias-Dachary
Javier Arias-Dachary
JMJosé M Melero
José M Melero
OBJECTIVES The decision about whether to use a biological or a mechanical prosthesis for aortic valve replacement remains controversial in patients between 50and 65years of age and has yet to be addressed in a Mediterranean population. This research aimed to analyse long-term survival and major morbidity rates (30-day mortality, stroke, any prosthetic reoperation and major bleeding) within this population. METHODS Our multicentre observational retrospective study included all subjects aged 50-65years who had a primary isolated aortic valve replacement due to severe aortic stenosis at 7 public hospitals from Andalusia (Spain) between 2000 and 2015. Concomitant surgery, reoperations and endocarditis were the exclusion criteria. A total of 1443 patients were enrolled in the study (272 with biological and 1171 with mechanical valves). Multivariate analyses including a 2:1 propensity score matching (506 mechanical and 257 biological prostheses) were conducted. RESULTS Bioprostheses were implanted in 18.8% (n=272): 35% were women; the mean EuroSCORE-I was 3%. The mean follow-up was 8.14.9years in a matched sample: 8.84.9years in those receiving a mechanical vs 7.1 +/- 4.5years in those receiving a biological prosthesis (P=0.001). In the paired sample, the 15-year survival rate was 73% in those who had a biological vs 76% in those who had a mechanical valve [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.54-1.20; P=0.159]. No significant differences were observed in patients >= 55years old (74% of 15-year survival in both groups: HR 0.88, 95% CI 0.56-1.34; P=0.527). A higher rate of major bleeding was found in patients with a mechanical prosthesis (P=0.004), whereas reoperation was more frequent among those with a biological prosthesis (P=0.01). CONCLUSIONS Long-term survival was comparable in patients above 55years of age. Mechanical prostheses were associated with more major bleeding and bioprostheses, with more reoperations. A bioprosthesis in patients above 55years old is a reasonable choice. Clinical trial registration number NCT03239509.

1 February 2023 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
EREmiliano Rodriguez-Caulo
Emiliano Rodriguez-Caulo
OBOscar R. Blanco-Herrera
Oscar R. Blanco-Herrera
EBElisabet Berastegui
Elisabet Berastegui
JAJavier Arias-Dachary
Javier Arias-Dachary
SSSouhayla Souaf-Khalafi
Souhayla Souaf-Khalafi
JOJ.J. Otero-Forero
J.J. Otero-Forero

27 March 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
DHDaniel Hernandez-Vaquero
Daniel Hernandez-Vaquero
EREmiliano Rodriguez-Caulo
Emiliano Rodriguez-Caulo
CVCarlota Vigil-Escalera
Carlota Vigil-Escalera
OBOscar Blanco-Herrera
Oscar Blanco-Herrera
EBElisabet Berastegui
Elisabet Berastegui
JSJacobo Silva
Jacobo Silva
: OBJECTIVES: Some researchers have observed an increased number of deaths during the follow-up of young patients who undergo aortic valve replacement due to severe aortic stenosis, suggesting that this procedure does not restore their life expectancy. Our goal was to confirm these findings and explore sex-based differences. METHODS: All patients between 50 and 65 years of age who underwent isolated aortic valve replacement in 27 Spanish centres during an 18-year period were included. We compared observed and expected survival at 15 years of follow-up and estimated the cumulative incidence of death from a competing risks point of view. We stratified by sex and analysed if being a woman was an independent risk factor for death. RESULTS: For men, the observed survival at 10 and 15 years of follow-up was 85% [95% confidence interval (CI) 83.6%–86.4%] and 72.3% (95% CI 69.7%–74.7%), respectively whereas the expected survival was 88.1% and 78.8%. For women, the observed survival at 10 and 15 years was 85% (95% CI 82.8%–86.9%) and 73% (95% CI 69.1%–76.4%), whereas the expected survival was 94.6% and 89.4%. At 15 years of follow-up, the cumulative incidence of death due to the disease in men and women was 8.2% and 16.7%, respectively. In addition, being a woman was an independent risk factor for death (hazard ratio = 1.23 (95% CI 1.02–1.48; P = 0.03). CONCLUSIONS: After the aortic valve replacement, men and women do not have their life expectancy restored, but this loss is much higher in women than in men. In addition, being a woman is a risk factor for long-term death. Reasons for these findings are unknown and must be investigated.

17 February 2018 in Trials
Verified
Journal Article
Open access
PDF file
EREmiliano Rodriguez-Caulo
Emiliano Rodriguez-Caulo
AGAna Guijarro-Contreras
Ana Guijarro-Contreras
JOJuan Otero-Forero
Juan Otero-Forero
MMMaría José Mataró
María José Mataró
GEGemma Sánchez Espín
Gemma Sánchez Espín
MJManuel Jiménez-Navarro
Manuel Jiménez-Navarro
During the last decade, the use of ministernotomy in cardiac surgery has increased. Quality of life and patient satisfaction after ministernotomy have never been compared to conventional full sternotomy in randomised trials. The aim of the study is to determine if this minimally invasive approach improves quality of life, satisfaction and clinical morbimortality outcomes. The QUALITY-AVR trial is a single-blind, single-centre, independent, and pragmatic randomised clinical trial comparing ministernotomy (“J” shaped upper hemisternotomy toward right 4th intercostal space) to full sternotomy in patients with isolated severe aortic stenosis scheduled for elective aortic valve replacement. One hundred patients will be randomised in a 1:1 computational fashion. Sample size was determined for the primary end point with alpha error of 0.05 and with power of 90% in detecting differences between intervention groups of ≥ 0.10 points in change from baseline quality of life Questionnaire EuroQOL-index (EQ-5D-5 L®), measured at 1, 6 or 12 months. Secondary endpoints are: the differences in change from other baseline EQ-5D-5 L® utilities (visual analogue scale, Health Index and Severity Index), cardiac surgery specific satisfaction questionnaire (SATISCORE®), a combined safety endpoint of four major adverse complications at 1 month (all-cause mortality, acute myocardial infarction, neurologic events and acute renal failure), bleeding through drains within the first 24 h, intubation time, postoperative hospital and intensive care unit length of stay, transfusion needs during the first 72 h and 1-year survival rates. Clinical follow up is scheduled at baseline, 1, 6, and 12 months after randomization. All clinical outcomes are recorded following the Valve Academic Research Consortium 2 criteria. The QUALITY-AVR trial aims to test the hypothesis that ministernotomy improves quality of life, satisfaction and clinical outcomes in patients referred for isolated aortic valve replacement. Statistically significant differences favouring ministernotomy could modify the surgical “gold standard” for aortic stenosis surgery, and subsequently the need to change the control group in transcatheter aortic valve implantation trials. Recruitment started on 18 March 2016. In November 2017, 75 patients were enrolled. ClinicalTrials.gov, NCT02726087. Registered on 13 March 2016.

8 October 2020 in The Heart Surgery Forum
Verified
Journal Article
Closed access
GEGemma Sánchez Espín
Gemma Sánchez Espín
JRJorge Rodríguez-Capitán
Jorge Rodríguez-Capitán
JFJuan José Otero Forero
Juan José Otero Forero
VMVíctor Manuel Becerra Muñoz
Víctor Manuel Becerra Muñoz
EREmiliano Rodriguez-Caulo
Emiliano Rodriguez-Caulo
MJManuel Jiménez-Navarro
Manuel Jiménez-Navarro
Background: Isolated tricuspid valve surgery is a rarely performed procedure and traditionally is associated with a bad prognosis, although its clinical outcomes still are little known. The aim of this study was to assess the short- and long-term clinical outcomes obtained at our center after isolated tricuspid valve surgery as treatment for severe tricuspid regurgitation. Methods: This retrospective study included 71 consecutive patients with severe tricuspid regurgitation who underwent isolated tricuspid valve surgery between December 1996 and December 2017. Perioperative and long-term mortality, tricuspid valve reoperation, and functional class were analyzed after follow up. Results: Regarding surgery, 7% of patients received a De Vega annuloplasty, 14.1% an annuloplasty ring, 11.3% a mechanical prosthesis, and 67.6% a biological prosthesis. Perioperative mortality was 12.7% and no variable was shown to be predictive of this event. After a median follow up of 45.5 months, long-term mortality was 36.6%, and the multivariate analysis identified atrial fibrillation as the only predictor (Hazard Ratio 3.014, 95% confidence interval 1.06-8.566; P = 0.038). At the end of follow up, 63.6% of survivors had functional class I. Conclusions: Isolated tricuspid valve surgery was infrequent in our center. Perioperative mortality was high, as was long-term mortality. However, a high percentage of survivors were barely symptomatic after follow up.